ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Alector, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.95+0.11 (+5.98%)

Close on Oct 19, 2026

Market cap: $216.89M
P/E (TTM): –
Dividend yield: –

Alector, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	66	35	76	156	331	51	91	67	32	51
Short-Term Investments	190	380	474	559	406	363	263	225	–	–
Cash & Short-Term Investments	256	415	550	714	737	415	355	292	32	51
Prepaid Expenses & Other	10	11	17	11	7.07	8.20	4.36	2.77	–	–
Total Current Assets	266	425	566	726	750	422	357	293	–	–
Property, Plant & Equipment	11	17	22	26	27	30	34	11	–	–
Gross Property, Plant & Equipment	48	50	50	48	45	41	39	13	–	–
Accumulated Depreciation	-37	-33	-28	-23	-17	-11	-5.41	-1.90	–	–
Operating Lease Right-of-Use Assets	14	20	25	28	31	32	28	31	–	–
Other Long-Term Assets	0.39	4.54	7.42	6.41	5.57	2.62	0.68	2.77	–	–
Total Assets	293	468	622	788	815	488	422	308	–	–
Accounts Payable	1.69	2.22	3.78	4.19	4.75	3.00	0.28	0.13	–	–
Accrued Expenses	19	29	30	28	27	23	18	8.44	–	–
Short-Term Debt	0.37	0	–	–	–	–	–	–	–	–
Current Portion of Long-Term Debt	0.37	–	–	–	–	–	–	–	–	–
Current Debt	0.73	0	–	–	–	–	–	–	–	–
Current Portion of Leases	9.06	8.75	8.46	8.06	7.80	7.51	6.57	–	–	–
Deferred Revenue (Current)	6.68	24	83	48	91	24	30	35	–	–
Total Current Liabilities	70	125	178	94	140	68	62	48	–	–
Long-Term Debt	9.32	9.39	0	–	–	–	–	–	–	–
Long-Term Leases	17	24	30	35	40	44	41	–	–	–
Operating Lease Liabilities	27	33	39	43	48	51	48	39	–	–
Other Long-Term Liabilities	1.74	1.23	1.37	0.76	0.16	0.47	0.49	0.10	–	–
Total Liabilities	263	342	488	573	514	221	227	195	–	–
Total Debt	10	9.39	0	–	–	–	–	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	–	–
Additional Paid-In Capital	1,003	956	844	799	748	677	414	17	–	–
Retained Earnings	-972	-829	-710	-580	-446	-410	-220	-114	–	–
Comprehensive Income & Other	0.17	0.26	0.18	-4.58	-0.94	0.61	0.14	-0.04	–	–
Shareholders' Equity	31	127	134	214	301	268	195	-97	-52	-25
Total Equity	31	127	134	214	301	268	195	-97	-52	-25
Total Liabilities & Equity	293	468	622	788	815	488	422	308	–	–
Shares Outstanding(shares)	110	99	85	83	82	79	69	14	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -912.4%
Net margin: -850.1%
Return on equity, FY2025: -181.6%

Financial strength

Current ratio: 5.26
Debt to equity: -0.99
Debt to assets: 4.9%
Cash to current liabilities: 175.0%

Valuation

P/E ratio: –
Price to sales: 15.65
Price to book: –
Dividend yield: –